QUIA Stock Overview
Engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Quia Pharma AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 0.036 |
52 Week High | SEK 0.14 |
52 Week Low | SEK 0.016 |
Beta | 0.44 |
11 Month Change | 90.53% |
3 Month Change | -9.27% |
1 Year Change | -15.22% |
33 Year Change | -99.95% |
5 Year Change | n/a |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
QUIA | SE Biotechs | SE Market | |
---|---|---|---|
7D | 7.1% | -5.8% | -2.1% |
1Y | -15.2% | 14.3% | 10.8% |
Return vs Industry: QUIA underperformed the Swedish Biotechs industry which returned 17.8% over the past year.
Return vs Market: QUIA underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
QUIA volatility | |
---|---|
QUIA Average Weekly Movement | 26.2% |
Biotechs Industry Average Movement | 9.3% |
Market Average Movement | 5.6% |
10% most volatile stocks in SE Market | 11.2% |
10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: QUIA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: QUIA's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | 3 | Marcus Bosson | www.quiapeg.com |
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.
Quia Pharma AB (publ) Fundamentals Summary
QUIA fundamental statistics | |
---|---|
Market cap | SEK 53.94m |
Earnings (TTM) | -SEK 13.86m |
Revenue (TTM) | SEK 4.99m |
10.8x
P/S Ratio-3.9x
P/E RatioIs QUIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QUIA income statement (TTM) | |
---|---|
Revenue | SEK 4.99m |
Cost of Revenue | SEK 1.30m |
Gross Profit | SEK 3.69m |
Other Expenses | SEK 17.55m |
Earnings | -SEK 13.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0093 |
Gross Margin | 73.94% |
Net Profit Margin | -277.59% |
Debt/Equity Ratio | 9.6% |
How did QUIA perform over the long term?
See historical performance and comparison